Neuronetics reported first-quarter 2026 revenue of $34.5 million, up 8% year over year. U.S. clinic revenue — largely from its Greenbrook network — rose 15% to $21.5 million, and the company shipped 34 NeuroStar systems in the U.S., a 10% increase versus the prior-year quarter.
The results reflect continued momentum in Neuronetics' combined device-and-clinic model following its acquisition of the Greenbrook TMS chain. Management highlighted the expanded Optum/United Behavioral Health policy allowing psychiatric mental health nurse practitioners to order, supervise, and administer NeuroStar as a driver of expected access gains, particularly in underserved communities.
The company framed 2026 as a year of clear growth opportunities alongside a push to reach sustained profitability.
NeuroStar remains one of the most widely used TMS systems in U.S. clinics, so its clinic-revenue growth and system placements are watched as a proxy for overall demand in the TMS market.
Source
Reporting based on coverage from Neuronetics. This article is editorial summary intended for general information; it is not medical advice.
